Mayo clinic study on ultracell
Final Report Submitted: February 8, 2018
Cannabidiol (CBD) is a non-psychoactive component of the industrial hemp plant. Cannabidiol is pleiotropic in that it produces many effects through multiple molecular pathways.
STUDY
This is a study with 20 subjects participating for a period of 12 hours. At the onset of this study each subject had blood drawn to set the Baseline of CBD in their bodies, each had a Baseline of 0.0mg of CBD baseline. Then each subject was given an oral dose of the Zilis supplement UltraCell CBD.
Each subject was given 4.12cc amounting to 10.9mg of Zilis Ultracell CBD. Blood tests were drawn every hour for a total of 12 hours.
This is a study with 20 subjects participating for a period of 12 hours. At the onset of this study each subject had blood drawn to set the Baseline of CBD in their bodies, each had a Baseline of 0.0mg of CBD baseline. Then each subject was given an oral dose of the Zilis supplement UltraCell CBD.
Each subject was given 4.12cc amounting to 10.9mg of Zilis Ultracell CBD. Blood tests were drawn every hour for a total of 12 hours.
CONCLUSION
The proprietary Ultracell absorption enhancer adds significant bioavailability to CBD. In this study, the average absorption after one hour was measured at 83%, with a maximum absorption up to 94%. Onset is quick and it has a lasting duration of product availability.
The proprietary Ultracell absorption enhancer adds significant bioavailability to CBD. In this study, the average absorption after one hour was measured at 83%, with a maximum absorption up to 94%. Onset is quick and it has a lasting duration of product availability.